ReviewFrontiers in immunology2018
New Vaccine Technologies to Combat Outbreak Situations.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 330 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
330 citing papers in PubMed, 1 synthesis or guideline pooled it, 588 citations in OpenAlex.
- Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects.Frontiers in immunology · 2022Pooled it
- Trial
- A dimeric mRNA vaccine based on key-mutant and KP.3 RBDs induces broad-spectrum immunity and protects mice against JN.1 and XDV challenges.Molecular biomedicine · 2026Article
- Immune Cell Signaling in Feline Infectious Peritonitis Virus Infection and Implications for Vaccine Design.Vaccines · 2026Review
- Homologous and Heterologous Immunization with a PIV5-Based Modified OspA Vaccine Confers Equivalent Protection Against Tick-TransmittedbioRxiv : the preprint server for biology · 2026Article
- Future Pneumococcal Vaccines: Shifting from Capsular Polysaccharides to Protein-Based Immunogens.Vaccines · 2026Review
- CD25 modulation enhances broadly neutralizing antibody response of SARS-CoV-2 subunit vaccine.Communications biology · 2026Article
- A GTPV-Based Murine Model Recapitulating Key Features of Lumpy Skin Disease for Preclinical Vaccine Evaluation.Animals : an open access journal from MDPI · 2026Article
- Article
- Vaccine cold chain and understanding what underpins vaccine security for vaccine preventable diseases.BMJ medicine · 2026Review
- The era of "Infectious Diseases+" has arrived: multi-disciplinary integration in pediatric infectious disease prevention and control.Frontiers in pediatrics · 2026Review
- Vaccination gaps in decentralized emergency response: understanding immunization barriers among volunteer firefighters. A cross-sectional mixed methods study.Frontiers in public health · 2026Article
- Review
- StealthX: A Versatile and Potent Exosome-Based Vaccine Platform for the Next Pandemic.Vaccines · 2025Review
- Post-authorisation effectiveness and safety study: a multicenter observational study of the effectiveness and safety of the inactivated SARS-CoV-2 vaccine.Clinical and experimental vaccine research · 2025Article
- Review
- A Programmable Finite-Replicated Organism Framework for Balanced Safety and Functionality.Life (Basel, Switzerland) · 2025Article
- Advances and Prospects of Fowl Adenoviruses Vaccine Technologies in the Past Decade.International journal of molecular sciences · 2025Review
- Next-Generation Vaccine Platforms: Integrating Synthetic Biology, Nanotechnology, and Systems Immunology for Improved Immunogenicity.Vaccines · 2025Review
- Review
270 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ever since the development of the first vaccine more than 200 years ago, vaccinations have greatly decreased the burden of infectious diseases worldwide, famously leading to the eradication of small pox and allowing the restriction of diseases such as polio, tetanus, diphtheria, and measles. A multitude of research efforts focuses on the improvement of established and the discovery of new vaccines such as the HPV (human papilloma virus) vaccine in 2006. However, radical changes in the density, age distribution and traveling habits of the population worldwide as well as the changing climate favor the emergence of old and new pathogens that bear the risk of becoming pandemic threats. In recent years, the rapid spread of severe infections such as HIV, SARS, Ebola, and Zika have highlighted the dire need for global preparedness for pandemics, which necessitates the extremely rapid development and comprehensive distribution of vaccines against potentially previously unknown pathogens. What is more, the emergence of antibiotic resistant bacteria calls for new approaches to prevent infections. Given these changes, established methods for the identification of new vaccine candidates are no longer sufficient to ensure global protection. Hence, new vaccine technologies able to achieve rapid development as well as large scale production are of pivotal importance. This review will discuss viral vector and nucleic acid-based vaccines (DNA and mRNA vaccines) as new approaches that might be able to tackle these challenges to global health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.